Professor Trent Woodruff
Professor

Trent Woodruff

Email: 
Phone: 
+61 7 336 52924

Background

Dr Woodruff is a Professor of Pharmacology who leads a research team aiming to find new therapeutic treatments for neurodegenerative disorders. Current therapies for these diseases are vastly inadequate, and so new research is needed to identify novel targets to slow or halt their progression. Prof Woodruff’s specific research revolves around the innate immune system in the brain, and the role of neuroinflammation in propagating disease. A key focus of his current work is testing new drugs developed at the University of Queensland in models of motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson's disease, as well as maintaining an active interest in acute inflammatory disorders including sepsis and ischemia-reperfusion injuries. Using a series of potent and orally active complement C5a and NLRP3 inflammasome inhibitors developed at UQ, Prof Woodruff's team has demonstrated the therapeutic potential of targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of these neurodegenerative diseases. His team has recently shown that in addition to their roles in neurodegeneration, innate immune factors also play essential roles in stem and neuronal cell development during embryogenesis, revealing the widespread physiological and pathological roles of this evolutionarily ancient immune system.

Availability

Professor Trent Woodruff is:
Available for supervision
Media expert

Fields of research

Immunology Neurosciences Pharmacology and pharmaceutical sciences

Qualifications

  • Bachelor (Honours) of Science (Advanced), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Neurodegenerative disease

    Studying new treatments to halt disease progression

  • Parkinson's disease

    Studying new treatments to halt disease progression

  • Motor neuron disease

    Studying new treatments to halt disease progression

Search Professor Trent Woodruff’s works on UQ eSpace

316 works between 2000 and 2025
All (316) Journal Article (235) Book Chapter (10) Conference Publication (70) Other Outputs (1)

201 - 220 of 316 works

2015

Journal Article

C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus

Mahajan, Supriya D., Parikh, Neil U., Woodruff, Trent M., Jarvis, James N., Lopez, Molly, Hennon, Teresa, Cunningham, Patrick, Quigg, Richard J., Schwartz, Stanley A. and Alexander, Jessy J. (2015). C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus. Immunology, 146 (1), 130-143. doi: 10.1111/imm.12489

C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus

2015

Journal Article

The role of C5a receptor signaling in endotoxin-induced miscarriage and preterm birth

Denny, Kerina J., Coulthard, Liam G., Mantovani, Susanna, Simmons, David, Taylor, Stephen M. and Woodruff, Trent M. (2015). The role of C5a receptor signaling in endotoxin-induced miscarriage and preterm birth. American Journal of Reproductive Immunology, 74 (2), 148-155. doi: 10.1111/aji.12386

The role of C5a receptor signaling in endotoxin-induced miscarriage and preterm birth

2015

Journal Article

Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signalling in the dorsal horn of the spinal cord

Khan, Nemat, Gordon, Richard, Woodruff, Trent M. and Smith, Maree T. (2015). Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signalling in the dorsal horn of the spinal cord. Pharmacology Research and Perspectives, 3 (3) e00137, 1-16. doi: 10.1002/prp2.137

Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signalling in the dorsal horn of the spinal cord

2015

Journal Article

Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis

Lee, Jia Y., Lee, John D., Phipps, Simon, Noakes, Peter G. and Woodruff, Trent M. (2015). Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 12 (1) 90, 90. doi: 10.1186/s12974-015-0310-z

Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis

2015

Journal Article

A commentary on: "NF kappa B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease". A cautionary note regarding C3aR

Woodruff, Trent M. and Tenner, Andrea J. (2015). A commentary on: "NF kappa B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease". A cautionary note regarding C3aR. Frontiers in Immunology, 6 (MAY) 220, 220. doi: 10.3389/fimmu.2015.00220

A commentary on: "NF kappa B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease". A cautionary note regarding C3aR

2015

Journal Article

The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury

Brennan, Faith H., Gordon, Richard, Lao, Hong W., Biggins, Patrick J., Taylor, Stephen M., Franklin, Robin J. M., Woodruff, Trent M. and Ruitenberg, Marc J. (2015). The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. Journal of Neuroscience, 35 (16), 6517-6531. doi: 10.1523/JNEUROSCI.5218-14.2015

The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury

2015

Journal Article

Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth

Coulthard, Liam G. and Woodruff, Trent M. (2015). Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. Journal of Immunology, 194 (8), 3542-3548. doi: 10.4049/jimmunol.1403068

Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth

2015

Journal Article

A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models

Benson, Melissa J, Thomas, Nicola K, Talwar, Sahil, Hodson, Mark P, Lynch, Joseph W, Woodruff, Trent M and Borges, Karin (2015). A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models. Neurobiology of Disease, 76, 87-97. doi: 10.1016/j.nbd.2015.02.004

A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models

2015

Journal Article

Properdin provides protection from Citrobacter rodentium-induced intestinal inflammation in a C5a/IL-6-dependent manner

Jain, Umang, Cao, Qi, Thomas, Nikhil A, Woodruff, Trent M, Schwaeble, Wilhelm J, Stover, Cordula M and Stadnyk, Andrew W (2015). Properdin provides protection from Citrobacter rodentium-induced intestinal inflammation in a C5a/IL-6-dependent manner. Journal of Immunology, 194 (7), 3414-3421. doi: 10.4049/jimmunol.1401814

Properdin provides protection from Citrobacter rodentium-induced intestinal inflammation in a C5a/IL-6-dependent manner

2015

Conference Publication

Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration

Kumar, Vinod, Lee, John, Noakes, Peter and Woodruff, Trent (2015). Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration. 8th International Conference on Complement Therapeutics, Chania, Crete, Greece, 1-6 January 2015.

Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration

2015

Conference Publication

Peripheral immune complement activation in neurodegenerative disease

Mantovani, S., Gordon, R., Ngo, S., Pfluger, C., O'Sullivan, J., Noakes, P., Henderson, R., McCombe, P. and Woodruff, T. (2015). Peripheral immune complement activation in neurodegenerative disease. 25th Biennial Meeting of the International-Society-for-Neurochemistry Jointly with the 13th Meeting of the Asian-Pacific-Society-for-Neurochemistry in Conjunction with the 35th Meeting of the Australasian-Neuroscience-Society, Cairns Australia, 23-27 August 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/jnc.13188

Peripheral immune complement activation in neurodegenerative disease

2015

Conference Publication

Investigating the role of C5a-CD88 signalling axis in diabetic nephropathy

Tan, S. M., Nguyen, T. V., Woodruff, T. M. and Coughlan, M. T. (2015). Investigating the role of C5a-CD88 signalling axis in diabetic nephropathy. 51st Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Canberra, Australia, 7-9 September, 2015. Richmond, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12543

Investigating the role of C5a-CD88 signalling axis in diabetic nephropathy

2015

Conference Publication

Paraquat activates the NLRP3 Inflammasome in microglia via the NADPH oxidase pathway

Albornoz, E., Deora, V., Robertson, B. A., Cooper, M. A., Schroder, K., Woodruff, T. M. and Gordon, R. (2015). Paraquat activates the NLRP3 Inflammasome in microglia via the NADPH oxidase pathway. International Congress of Immunology (ICI), Melbourne, Australia, Aug 21-26, 2016. Weinheim, Germany: Wiley-Blackwell.

Paraquat activates the NLRP3 Inflammasome in microglia via the NADPH oxidase pathway

2015

Conference Publication

Unexpected activities of the complement pathway in migrating neurons

Reiner, O., Gorelik, A., Sapir, T., Bialas, A. R., Stevens, B., Woodruff, T. M. and Haffner-Krausz, R. (2015). Unexpected activities of the complement pathway in migrating neurons. 25th Biennial Meeting of the International Society for Neurochemistry Jointly with the 13th Meeting of the Asian Pacific Society for Neurochemistry in Conjunction with the 35th Meeting of the Australasian Neuroscience Society, Cairns, QLD Australia, 23-27 August 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/jnc.13185

Unexpected activities of the complement pathway in migrating neurons

2014

Journal Article

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a

Halai, Reena, Bellows-Peterson, Meghan L., Branchett, Will, Smadbeck, James, Kieslich, Chris A., Croker, Daniel E., Cooper, Matthew A., Morikis, Dimitrios, Woodruff, Trent M., Floudas, Christodoulos A. and Monk, Peter N. (2014). Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. European Journal of Pharmacology, 745, 176-181. doi: 10.1016/j.ejphar.2014.10.041

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a

2014

Journal Article

Brief report: Complement C5a promotes human embryonic stem cell pluripotency in the absence of FGF2

Hawksworth, Owen A., Coulthard, Liam G., Taylor, Stephen M., Wolvetang, Ernst J. and Woodruff, Trent M. (2014). Brief report: Complement C5a promotes human embryonic stem cell pluripotency in the absence of FGF2. Stem Cells, 32 (12), 3278-3284. doi: 10.1002/stem.1801

Brief report: Complement C5a promotes human embryonic stem cell pluripotency in the absence of FGF2

2014

Journal Article

Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods

Khan, Nemat, Woodruff, Trent M. and Smith, Maree T. (2014). Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. Pharmacology Biochemistry and Behavior, 126, 13-27. doi: 10.1016/j.pbb.2014.09.003

Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods

2014

Journal Article

Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis

Gu H., Mickler E.A., Cummings O.W., Sandusky G.E., Weber D.J., Gracon A., Woodruff T., Wilkes D.S. and Vittal R. (2014). Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB Journal, 28 (10), 4223-4234. doi: 10.1096/fj.13-247650

Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis

2014

Journal Article

Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood

Mantovani, S., Gordon, R., Macmaw, J. K., Plfluger, C. M., Henderson, R. D., Noakes, P. G., McCombe, P. A. and Woodruff, T. M. (2014). Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. Journal of Neuroimmunology, 276 (1-2), 213-218. doi: 10.1016/j.jneuroim.2014.09.005

Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood

2014

Journal Article

Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking

Tamamis, Phanourios, Kieslich, Chris A., Nikiforovich, Gregory V., Woodruff, Trent M., Morikis, Dimitrios and Archontis, Georgios (2014). Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking. BMC Biophysics, 7 (1) 5, 1-16. doi: 10.1186/2046-1682-7-5

Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking

Current funding

  • 2024 - 2027
    Preclinical development of complement C5a receptor 2 modulators for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2024 - 2025
    Examining the efficacy of monepantel in the 6-OHDA model of Parkinson's disease
    PharmAust Limited
    Open grant
  • 2024 - 2025
    Investigating the pharmacological activity of monepantel on autophagy in the NSC-34 motor neuron cell line
    PharmAust Limited
    Open grant
  • 2024 - 2026
    Developing novel peptide tracers for improving immunotherapy outcomes
    NHMRC Development Grant
    Open grant
  • 2022 - 2025
    Therapeutic Inhibition of Neutrophil Activity as a Disease-Modifying Treatment for Amyotrophic Lateral Sclerosis
    United States Congressionally Directed Medical Research Programs - Amyotrophic Lateral Sclerosis Research Program
    Open grant
  • 2022 - 2025
    Making peptides orally bioavailable
    ARC Discovery Projects
    Open grant
  • 2022 - 2026
    Developing new therapies targeting innate immune mediated inflammation in neurodegenerative disease
    NHMRC Investigator Grants
    Open grant

Past funding

  • 2023 - 2024
    Therapeutic potential of targeting one of the core players of inflammation (Inflammasome) in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    C9orf72 dipeptide-mediated activation of microglia as a therapeutic target for MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    Inhibiting complement C5a receptors to improve heart function in type 2 diabetes (DARP Grant administered by Monash University
    Monash University
    Open grant
  • 2022 - 2024
    Profiling monocytes in MND to assess disease progression and heterogeneity
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2023
    An integrated analytical network for protein characterisation
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2022 - 2024
    Developing FXIIa inhibitors as next-generation anticoagulants
    NHMRC Development Grant
    Open grant
  • 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND
    Motor Neurone Disease Research Institute of Australia Inc Linda Rynalski Bridge Funding Grant
    Open grant
  • 2021 - 2023
    Complement C5aR1: A novel therapeutic target for brain cancer
    Brain Cancer Innovation Project Grants
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2021
    Inflammatory biomarkers in 6-OHDA mouse model of Parkinson's disease
    UniQuest Pty Ltd
    Open grant
  • 2020 - 2024
    Preclinical development of centrally active complement C3a receptor modulators as disease-modifying drugs for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2020 - 2022
    Investigating the PROfile of complement activation in relation to Vasospasm, delayed cerebral Ischaemia and aneurysmal Subarachnoid haemorrhage Outcomes (ProcVISO Study) (administered by RBWH)
    Metro North Hospital and Health Service
    Open grant
  • 2020 - 2021
    Transcriptomic and Functional Evaluation of Immune-Activated Monocytes in MND.
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2020 - 2022
    Eph receptor blockade to prevent and repair endothelial damage in systemic inflammation
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019
    A versatile accurate mass, high resolution QTOF mass spectrometer for chemistry and proteomic applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019
    Advanced Brightfield and Fluorescent High Speed and Throughput Slide Scanner for biological, medical, materials science, and agricultural applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019 - 2023
    Harnessing the Innate Immune System to Target Cancer: A Novel Immunotherapeutic Strategy for Solid Tumours
    NHMRC Development Grant
    Open grant
  • 2019 - 2020
    Role of NLRP3 inflammasome activation in the prognosis of secondary progressive multiple sclerosis
    Metro North Hospital and Health Service
    Open grant
  • 2019 - 2022
    Understanding the mechanism of action for intravenous immunoglobulin (IVIG) therapy in spinal cord injury
    NHMRC Project Grant
    Open grant
  • 2018 - 2019
    Targeting peripheral inflammatory pathology in Parkinson's disease using repurposed drugs
    Wesley Medical Research Ltd
    Open grant
  • 2018 - 2019
    Therapeutic inhibition of the terminal complement pathway as a disease-modifying treatment for motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic testing of the clinical candidate drug PMX205 in a TDP43-based model of MND and its mechanism
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2020
    Therapeutic potential of inhibiting Eph/ephrin signalling to repair the vascular endothelium in septic shock
    NHMRC Project Grant
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    A potential role for C5a antagonism in the medical management of feline hypertrophic cardiornyopathy
    Peter & Mary Ellen Stone Memorial Fund
    Open grant
  • 2017 - 2019
    Defining inflammatory biomarkers in motor neuron disease patients to assist in clinical trial efficiency of the C5aR antagonist PMX205
    Wesley Medical Research Ltd
    Open grant
  • 2017 - 2020
    New Treatments for Brain Disease
    Queensland Government Advance Queensland Innovation Partnerships
    Open grant
  • 2017 - 2023
    The Queensland Drug Repurposing Initiative
    Queensland Government Advance Queensland Innovation Partnerships
    Open grant
  • 2017 - 2019
    Is there a potential therapeutic role for Eph/ephrin signalling blockade in children with severe sepsis?
    Financial Markets Foundation for Children
    Open grant
  • 2017 - 2018
    Therapeutic inhibition of HMGB1 to slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2017 - 2021
    Preclinical Development of Complement C5aR Antagonists for the Treatment of Motor Neuron Disease
    NHMRC Development Grant
    Open grant
  • 2016 - 2018
    Pharmacological Targeting of Proinflammatory Kinase Signalling in Parkinson's disease
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2016 - 2020
    Blocking inflammasome-induced neuroinflammation in PD with a potent, orally available small molecule
    The Michael J Fox Foundation Therapeutic Pipeline Program
    Open grant
  • 2016 - 2018
    Is there a potential therapeutic role for Eph/ephrin signalling blockade in patients with septic shock?
    Bayer Pharma AG
    Open grant
  • 2016 - 2017
    Development of complement C5aR1 antagonists for the treatment of motor neuron disease
    UQ Collaboration and Industry Engagement Fund - FirstLink
    Open grant
  • 2016 - 2017
    Exploiting the opposing actions of complement receptors C3aR and C5aR1 in the treatment of MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016 - 2020
    Therapeutic targeting of neuroinflammation to slow the progression of neurodegenerative disease
    NHMRC Career Development Fellowship
    Open grant
  • 2016
    Exosome and Bio/Nanoparticle Characterisation Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2016 - 2018
    Targeting the Complement Cascade: A Novel Therapeutic Strategy for Metastatic Melanoma
    NHMRC Project Grant
    Open grant
  • 2015 - 2017
    Pharmacological targeting of the NLRP3 inflammasome in pre-clinical models of Parkinson's disease using a potent orally active inhibitor
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2015 - 2017
    Complement activation as a therapeutic target and clinical biomarker for Parkinson's disease
    NHMRC Project Grant
    Open grant
  • 2015 - 2020
    Determining the contribution of peripheral immune complement signalling in the progression of motor neuron disease
    NHMRC Project Grant
    Open grant
  • 2015 - 2017
    Inhibitors of NLRP3 activation for treatment of inflammatory CNS diseases
    NHMRC Project Grant
    Open grant
  • 2015
    Therapeutic targeting of inflammation in Parkinson's disease
    RL Cooper Medical Research Foundation Limited
    Open grant
  • 2015 - 2016
    Therapeutic targeting of the NLRP3 inflammasome using a potent and orally active inhibitor in experimental MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2014 - 2015
    Development of a rapid ex vivo screening assay for immunotoxicity of nanoparticles
    UQ Collaboration and Industry Engagement Fund - Seed Research Grant
    Open grant
  • 2014
    Innate immune complement signalling in peripheral immune cells during the progression of motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2013
    Establishment of an Integrated Facility for Single Cell Analysis
    UQ Major Equipment and Infrastructure
    Open grant
  • 2012 - 2016
    Investigating the Role of the Innate Immune Complement System in the Abnormal Development of the Central Nervous System
    ARC Future Fellowships
    Open grant
  • 2012 - 2014
    Contribution of Complement C5a to Neuronal Cell Death during Ischemic Stroke
    NHMRC Project Grant
    Open grant
  • 2012
    Establishment of Integrated Small Animal Metabolic and Physiology Assessment Facility
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011 - 2013
    Microdialysis to monitor fluid shifts and predict organ failure in the systemic inflammatory response syndrome
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2011
    A Multi-Channel Fluorescence Plate Reader for Studying Receptor-Ligand Interactions
    NHMRC Equipment Grant
    Open grant
  • 2011
    Building UQ's analytical capacity in biomedical sciences
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011
    Molecular Stereology Facility Upgrade
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011
    Real time regional tissue analysis suite
    UQ Major Equipment and Infrastructure
    Open grant
  • 2011 - 2013
    The role of the innate immune system during the progression of motor neuron disease; the search for new therapeutic targets
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2011 - 2013
    Therapeutic Targeting of Complement C5a Receptors in Huntington's Disease
    NHMRC Project Grant
    Open grant
  • 2010 - 2012
    Therapeutic modulation of the innate immune complement system as a new and adjunct therapy to treat a wide variety of cancers
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2010 - 2013
    Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases
    ARC Linkage Projects
    Open grant
  • 2010 - 2012
    Complement activation in experimental epilepsy: role of C5a receptors
    NHMRC Project Grant
    Open grant
  • 2010
    In Situ Hybridization Suite for Biomedical Science Researchers
    NHMRC Equipment Grant
    Open grant
  • 2010 - 2011
    Notch-1 contributes to neuronal cell death and glial inflammation by modulating NFkappaB activity in ischaemic stroke
    National Heart Foundation of Australia
    Open grant
  • 2009 - 2011
    Characterizing novel therapeutic interventions in a new model of focal retinopathy
    NHMRC Project Grant
    Open grant
  • 2009 - 2013
    Complement C5a Receptors , Placental Inflammation and Reproductive Impairment.
    NHMRC Project Grant
    Open grant
  • 2009
    Liquid Scintillation Spectroscopy Facility
    UQ School/Centre Co-Funding
    Open grant
  • 2009
    Role of Complements Anaphylatoxin Receptors in Experimental Stroke
    UQ Early Career Researcher
    Open grant
  • 2008 - 2010
    Characterisation of the effect of C5a receptor antagonists against the C5a-like receptor 2 (C5L2)
    UQ New Staff Research Start-Up Fund
    Open grant
  • 2008 - 2010
    Establishment of therapeutically relevant animal models and markers for Crohn's Disease
    ARC Linkage Projects
    Open grant
  • 2008 - 2012
    NHMRC Career Development Award (Biomedical - Level 1): The role of the complement system in neurodegeneration and the therapeutic potential of complement inhibition
    NHMRC Career Development Award
    Open grant
  • 2008
    Role of the complement system in the healthy and diseased central nervous system
    ARC Discovery Projects
    Open grant
  • 2007 - 2008
    Scientific Visit - Protective actions of novel anti-inflammatory agents in neurotoxin-damaged neuronal cultures mimicking Parkinson's disease
    Australian Academy of Science
    Open grant
  • 2005
    The effectiveness of C5a receptor antagonists in the treatment of motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant

Availability

Professor Trent Woodruff is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Role of immune and inflammatory pathways in the progression of neurodegenerative disease

Supervision history

Current supervision

Completed supervision

Enquiries

Contact Professor Trent Woodruff directly for media enquiries about:

  • Drug Development
  • Huntington's disease
  • motor neuron disese
  • Neurodegenerative disease
  • Parkinson's disease

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au